Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

A 20-year-old male experienced significant hair regrowth and reduced shedding after four months of using 2.5mg oral minoxidil, 1mg oral finasteride, and weekly 1.5mm derma stamping. He reported no side effects from the treatments and noted increased hair growth in other areas of his body.

The user observed some regrowth and longer baby hairs after one month of using finasteride, despite experiencing increased shedding. They noted no side effects except for clear semen.

PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.

A 54-year-old user shares progress after 3 years on dutasteride, following 15 years on finasteride, using 0.5 mg/day dutasteride, topical minoxidil every other day, and a peptide serum on alternate days. They experienced a significant shed during the transition but are now maintaining hair, noticing some new growth along the hairline.

The user continues to experience hair loss despite using dutasteride 2.5mg, minoxidil 5mg, and ciclopirox shampoo, and plans to reassess after one year. Others report similar issues with dutasteride, with some switching to finasteride or adding RU58841.

GT20029 is a topical treatment that degrades androgen receptors to prevent hair thinning and loss, potentially offering fewer side effects than systemic treatments like finasteride. Concerns include its impact on hair texture and potential systemic effects, with market availability speculated in 3 to 5 years.

Clascoterone results are anticipated to be released in fall 2026, possibly at the EADV conference. Users express skepticism and humor about the release date.

A 26-year-old has seen hair improvement after 18 months on finasteride, with no side effects, and is considering switching to dutasteride despite difficulty obtaining a prescription. They also use dermastamping and are hesitant to try minoxidil, preferring to explore dutasteride first.

Dutasteride, at 1 mg daily, was used for hair regrowth, with initial shedding and side effects like watery semen and increased libido. The user previously tried finasteride and minoxidil but switched to dutasteride for stronger, sustained results.

The user shared their 9-month hair regrowth progress using topical Minoxidil 5%, finasteride 0.05%, retinoic acid 0.01%, dermastamping, ketoconazole shampoo, and supplements like biotin. They experienced some hair density improvement but minimal change in the hairline, with initial side effects from finasteride that resolved after dosage adjustment.

The conversation is about the anticipated release date of phase II results for a hair loss treatment called GT20029 and the cautious optimism surrounding it due to past disappointments with similar treatments. Users expect an update in the next few months.

A 23-year-old male has been using oral finasteride and topical minoxidil for 14 months, along with derma stamping and vitamins, but is considering switching to dutasteride due to dissatisfaction with progress. Users suggest cutting hair shorter to better track progress, and some recommend adding dutasteride and possibly a hair transplant in the future.

Long-term finasteride users often experience periodic hair shedding due to natural hair cycles, even after several years of use. Some consider switching to dutasteride, but concerns about side effects and the effectiveness of finasteride remain common.

A 22-year-old is using 0.025% topical finasteride and 6% minoxidil nightly, seeing new hair growth and reduced hair loss. They are considering increasing finasteride dosage but are cautious about potential side effects.

The conversation is about hair regrowth progress using hormone replacement therapy (HRT) with Estradiol and Cyproterone, without using Minoxidil. The user shares progress pictures over 0, 3, and 6 months.

Spironolactone and finasteride are not recommended for women planning pregnancy due to birth defect risks. Both need to be stopped months before conception, and finasteride is generally not advised for women.

The user experienced significant hair regrowth using spironolactone, estradiol, minoxidil, and finasteride while transitioning. They noted reduced libido and increased grogginess as side effects.

The user has been using a regimen of 1mg finasteride daily, minoxidil foam 5% twice a day, and recently added oral Dutasteride 0.5 mg once a week, showing noticeable progress in hair growth over 3 months and 1 week. The feedback is positive, encouraging consistency and patience for continued improvement.

A 35-year-old male is experiencing hair loss due to AGA and stress, using Minoxidil and finasteride for treatment. Users suggest waiting longer for results, considering additional treatments like microneedling, and consulting a dermatologist for scalp issues.

User shared 13 months of progress using finasteride, microneedling, vitamins, and scalp care, and recently started stemoxydine. The post includes before and after photos.

A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.

A 22-year-old female with AGA due to PCOS is using 5% minoxidil foam and 2mg finasteride daily, and is seeking advice on microneedling frequency and safety. Concerns about finasteride dosage and its effects on PCOS were discussed, with emphasis on trusting the prescribed treatment plan.

A 48-year-old reported significant hair regrowth after two years using finasteride and minoxidil, with better results on the temples and using a dermastamp for the crown. The user experienced no side effects from the treatments.

Clascoterone phase 3 results show promising improvements in hair count, but concerns about high costs and lack of detailed data remain. Users compare it to existing treatments like Minoxidil and Finasteride, expressing skepticism about its accessibility and effectiveness.

Clascoterone is a topical treatment for androgenetic alopecia, showing modest to moderate hair regrowth, and may be available by 2027-2028. It is considered safer than finasteride, with discussions on its effectiveness compared to RU58841 and pyrilutamide.

Clascoterone's full trial results are expected by mid-July 2026, but skepticism exists about timely release. Clascoterone is available at 5% from some telehealth companies.

A 17-year-old is using oral dutasteride, finasteride, and topical minoxidil for hair loss, with plans to increase dutasteride and consider surgery. They report significant regrowth but are worried about side effects and the effects of blocking DHT at a young age.

The user is considering increasing their dutasteride dose and trying clascoterone or RU58841 for hair loss stabilization. They have used finasteride, minoxidil, and dutasteride, with some success but recent setbacks.

A 32-year-old male used 1.25mg oral finasteride daily and 1ml topical minoxidil twice daily for 24 weeks, experiencing improved skin and hair growth with initial side effects that resolved after three weeks. He plans to try dermastamping to address a stubborn cowlick area.

The user has experienced limited hair regrowth using 1mg oral finasteride, topical minoxidil foam, and occasional dermarolling since August 2023. They are considering switching to dutasteride, adding oral minoxidil 2.5 mg, and RU58841 to improve results.